Celldex Therapeutics (CLDX) ) Reports Q4 Results

Celldex Therapeutics, Inc. (CLDX) shares are up 0.70% to $24.90 in pre-market trading Tuesday following the company’s fourth quarter earnings results.

The clinical-stage firm reported earnings of ($0.36) per share on revenues of $1.5 million, up 150% from a year ago. Analysts were expecting EPS of ($0.34) on revenues of $490K.

Net loss came in at $31.8 million, or ($0.36) per share, for the fourth quarter of 2014 and $118.1 million, or ($1.32) per share, for the twelve months ended Dec. 31, 2014, compared to a net loss of $22.1 million, or ($0.27) p/sh and $81.6 million, or ($1.02) p/sh for the comparable periods in 2013.

On valuation measures, Celldex Therapeutics Inc. shares, which currently have an average 3-month trading volume of 2.07 million shares, have a median Wall Street price target on the name of $33.00 with a high target of $45.00. Currently ticker boasts 9 ‘Buy’ endorsements, compared to no ’Holds’ and no ‘Sell’.

Profitability-wise, CLDX has a t-12 operating margin and price/sales of (4,122%) and 811.85, respectively. The $2.22 billion market cap company reported $201 million in cash vs. zero in debt in its most recent quarter.

CLDX currently prints a one year loss of about 22%, and a year-to-date return of around 35.50%.

The chart below shows where the equity has traded over the last 52 weeks.

Celldex Therapeutics Inc. is a Hampton, New Jersey- based biopharmaceutical company that focuses on the development of novel therapeutics for human health care primarily in the United States.

Create Content With AI

Try TradingView For Free

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.